EU Regulatory Procedures In The Pharmaceutical Sector

Law360, New York (July 22, 2010, 1:58 PM EDT) -- On July 1, 2010, the European Union’s General Court upheld a 2005 decision from the European Commission that found that AstraZeneca PLC had abused its dominant position by preventing or delaying the marketing of a generic version of its Losec (omeprazole) product and hindering parallel imports of Losec capsules in certain countries.

Losec is a proton pump inhibitor used in the treatment of acid-related gastric diseases.

In 2005 the EC had found that AstraZeneca had abused its dominant position by: providing deliberately misleading information to patent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.